Fig. 1

miR-133a-3p expression is reduced in PCa tissues and further downregulated in bone metastatic PCa tissues. a miR-133a-3p expression levels was decreased in PCa tissues compared with that in adjacent normal tissues (ANT) by analyzing the PCa miRNA sequencing dataset from TCGA (ANT, n = 52; PCa, n = 498). b miR-133a-3p expression levels was reduced in 52 paired PCa tissues compared with that in the matching ANT by analyzing the PCa miRNA sequencing dataset from TCGA. c miR-133a-3p expression levels was further decreased in the primary tumors of the patients with bone metastases (BM) compared with that in the primary tumors of the patients without bone metastases (non-BM) by analyzing the PCa miRNA sequencing dataset from TCGA. (non-BM, n = 11; BM, n = 9). d Real-time PCR analysis of miR-133a-3p expression in 48 benign prostate lesions tissues and 245 PCa tissues. Transcript levels were normalized to U6 expression. Lines represent median and lower/upper quartiles. e Real-time PCR analysis of miR-133a-3p expression in 20 paired PCa tissues (miR-133a-3p expression level in PCa tissues: miR-133a-3p expression level in ANT). Transcript levels were normalized to U6 expression. f Real-time PCR analysis of miR-133a-3p expression in 201 non-bone metastatic and 13 bone metastatic PCa samples. Transcript levels were normalized to U6 expression. Lines represent median and lower/upper quartiles. *P < 0.05. g Real-time PCR analysis of miR-133a-3p expression levels in normal prostate epithelial cell (RWPE-1), primary PCa cell 22RV1, bone metastatic PCa cell lines (PC-3, C4-2B and VCaP) and brain metastatic cell line DU145 and lymph node metastatic cell line LNCaP. Transcript levels were normalized to U6 expression. *P < 0.05